^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

CXCL10 overexpression

i
Other names: CXCL10 (Chemokine (C-X-C motif) ligand 10)
Entrez ID:
Related biomarkers:
1year
Pirfenidone Antagonizes TGF-β1-Mediated Gabapentin Resistance via Reversal of Desmoplasia and the 'Cold' Microenvironment in Pancreatic Cancer. (PubMed, Cancer Lett)
Hmox1highiCAFs overexpressed the Cxcl10 receptor (Sdc4) and facilitated functional CD8+ T-cell infiltration through the Tnfsf9-Tnfrsf9 axis. Overall, our nanodrugs reshape the phenotype of CAFs and enhance functional CD8+ T-cell infiltration into tumors, holding the potential to be a safe and promising therapy for PDAC.
Journal
|
CD8 (cluster of differentiation 8) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • TNFRSF9 (TNF Receptor Superfamily Member 9) • HMOX1 (Heme Oxygenase 1) • SDC4 (Syndecan 4) • TGFB1 (Transforming Growth Factor Beta 1)
|
CXCL10 overexpression • HMOX1 expression • CXCL10 expression • HMOX1 overexpression
over1year
Calycosin (CA) inhibits proliferation, migration and invasion by suppression of CXCL10 signaling pathway in glioma. (PubMed, Aging (Albany NY))
Finally, we verified that calycosin inhibited glioma growth in a xenograft mouse model and downregulated CXCL10 and its downstream molecules. These findings suggest that targeting CXCL10 may be an effective strategy in glioblastoma treatment, and calycosin emerges as a potential therapeutic agent.
Journal
|
CXCL10 (Chemokine (C-X-C motif) ligand 10) • IL1B (Interleukin 1, beta) • NLRP3 (NLR Family Pyrin Domain Containing 3)
|
CXCL10 overexpression • CXCL10 expression
2years
Multifunctional natural killer cell engager releasing CXCL10 augments natural killer cell recruitment and anti-tumor efficacy against glioblastoma (SITC 2023)
Our novel NKCE which has the ability to responsively and locally release CXCL10 induced NK cell migration and boosted NK cell anti-tumor activity against solid tumors. Such a multi-specific approach not only activates NK cells locally, but promotes their recruitment and retention in the TME.
Clinical • IO biomarker
|
CXCL10 (Chemokine (C-X-C motif) ligand 10) • CXCR3 (C-X-C Motif Chemokine Receptor 3)
|
CXCL10 overexpression • CXCL10 expression
over2years
CXCL10 mediates CD8 T cells to facilitate vessel normalization and improve the efficacy of cetuximab combined with PD-1 checkpoint inhibitors in colorectal cancer. (PubMed, Cancer Lett)
Elevated CXCL10 expression sensitized colorectal cancer cells to cetuximab/anti-PD1 combination therapy compared with cetuximab or anti-PD1 alone. We propose that CXCL10 could be used to increase the anti-EGFR therapy and immunotherapy effect, targeting both tumor vessels and immune cells in colorectal cancer.
Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • CXCL10 (Chemokine (C-X-C motif) ligand 10)
|
CXCL10 overexpression • CXCL10 expression
|
Erbitux (cetuximab)
over2years
Circ_0001667 accelerates breast cancer proliferation and angiogenesis through regulating CXCL10 expression by sponging miR-6838-5p. (PubMed, Thorac Cancer)
Circ_0001667 is involved in breast cancer cell proliferation and angiogenesis through regulation of the miR-6838-5p/CXCL10 axis.
Journal
|
CXCL10 (Chemokine (C-X-C motif) ligand 10)
|
CXCL10 overexpression
3years
A systemic study on the vulnerability and fatality of prostate cancer patients towards COVID-19 through analysis of the TMPRSS2, CXCL10 and their co-expressed genes. (PubMed, Genomics Inform)
We observed that TMPRSS2 and CXCL10, together with their often co-expressed genes, are important in the binding activity and immune responses in prostate cancer and COVID-19 infection, respectively. Finally, we found that TMPRSS2 and CXCL10 are two putative biomarkers responsible for the increased vulnerability and fatality of prostate cancer patients to COVID-19.
Journal
|
CXCL10 (Chemokine (C-X-C motif) ligand 10) • TMPRSS2 (Transmembrane serine protease 2)
|
CXCL10 overexpression
3years
Multifunctional Natural Killer Cell Engager Releasing CXCL10 Augments Natural Killer Cell Recruitment and Anti-tumor Efficacy against Glioblastoma (SITC 2022)
Our novel NKCE within a locally-cleavable CXCL10 domain induced NK cell migration and boosted NK cell anti-tumor activity against solid tumors. Such a multi-specific approach not only activates NK cells locally but promotes their recruitment and retention in the TME.
Clinical • IO biomarker
|
CXCL10 (Chemokine (C-X-C motif) ligand 10) • IL13RA2 (Interleukin 13 Receptor Subunit Alpha 2) • CXCR3 (C-X-C Motif Chemokine Receptor 3)
|
CXCL10 overexpression
over3years
Multifunctional Natural Killer Cell Engager Releasing CXCL10 Augments Natural Killer Cell Recruitment and Anti-tumor Efficacy Against Glioblastoma (ASGCT 2022)
Our results demonstrated that the CXCR3-CXCL10 axis contributes to the recruitment of NK cells to tumor sites without effect on the anti-tumor capacity of NK cells. Our novel natural killer cell engager within a specific locally-cleavable CXCL10 domain not only induced enhanced NK cell migration and infiltration into tumor sites but also boosted NK cell anti-tumor activity, representing a promising strategy to facilitate the recruitment of NK cells and therapeutic efficacy against solid tumors.
Clinical • IO biomarker
|
CXCL10 (Chemokine (C-X-C motif) ligand 10) • IL13RA2 (Interleukin 13 Receptor Subunit Alpha 2) • CXCR3 (C-X-C Motif Chemokine Receptor 3) • IL15 (Interleukin 15)
|
CXCL10 overexpression
4years
Screening of CXC chemokines in the microenvironment of ovarian cancer and the biological function of CXCL10. (PubMed, World J Surg Oncol)
In conclusion, we hope that our data will provide new insights into the development of immunotherapy and the selection of prognostic markers for patients with OC.
Journal • IO biomarker
|
CXCL10 (Chemokine (C-X-C motif) ligand 10) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • CXCL11 (C-X-C Motif Chemokine Ligand 11) • CXCL1 (Chemokine (C-X-C motif) ligand 1)
|
CXCL10 overexpression
4years
CXCL10/CXCR3 signaling contributes to an inflammatory microenvironment and its blockade enhances progression of murine pancreatic precancerous lesions. (PubMed, Elife)
Blocking of CXCL10/CXCR3 signaling in vivo shifts macrophage populations to a tumor promoting (Ym1, Fizz, Arg1) phenotype, increases fibrosis and mediates progression of lesions, highlighting the importance of this pathway in PDA development. This is reversed when CXCL10 is overexpressed in PanIN cells.
Preclinical • Journal
|
IFNG (Interferon, gamma) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • CXCR3 (C-X-C Motif Chemokine Receptor 3)
|
CXCL10 overexpression
over4years
PRMT5 promotes inflammation of cigarette smoke extract-induced bronchial epithelial cells by up-regulation of CXCL10. (PubMed, Allergol Immunopathol (Madr))
Knockdown of PRMT5 promoted cell viability of cigarette smoke extract-induced 16HBE, and reduced inflammation through down-regulation of CXCL10.
Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • PRMT5 (Protein Arginine Methyltransferase 5) • IL1B (Interleukin 1, beta)
|
CXCL10 overexpression • CXCL8 expression • IL6 expression